The Patent Finder

Janssen Biopharma, Inc.

14 patents currently held · Updated Nov 17, 2026
21 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

Previously recorded as Alios Biopharma, Inc. (to 2019)

0
Ending by 2030
Dec 2033
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 4, 2026
    The maintenance fee for Substituted nucleosides, nucleotides and analogs thereof (US 10,307,439) comes due Dec 4, 2026. Unpaid by Jun 4, 2027, it lapses early.
  • 1 fee due Feb 6, 2027
    The maintenance fee for Substituted nucleosides, nucleotides and analogs thereof (US 10,370,401) comes due Feb 6, 2027. Unpaid by Aug 6, 2027, it lapses early.
  • 1 fee due May 26, 2027
    The maintenance fee for Substituted Nucleosides, Nucleotides and Analogs Thereof (US 10,487,104) comes due May 26, 2027. Unpaid by Nov 26, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 19, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 10,112,966Substituted Nucleosides, Nucleotides and Analogs Thereof
In force
 · High confidence
In forceHigh confidence
US 10,144,755Substituted Nucleosides, Nucleotides and Analogs Thereof
In force
 · High confidence
In forceHigh confidence
US 10,487,104Substituted Nucleosides, Nucleotides and Analogs Thereof
In force
 · High confidence
In forceHigh confidence
US 10,683,320Substituted Nucleosides, Nucleotides and Analogs Thereof
In force
 · High confidence
In forceHigh confidence
US 10,793,591Substituted Nucleosides, Nucleotides and Analogs Thereof
In force
 · High confidence
In forceHigh confidence
US 10,702,523AZA-pyridone compounds and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,370,401Substituted nucleosides, nucleotides and analogs thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,307,439Substituted nucleosides, nucleotides and analogs thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,472,826Acyclic Antivirals
In force
 · Low confidence
In forceLow confidence
US 12,077,757Modified Oligonucleotides and Methods of Use
In force
 · Low confidence
In forceLow confidence
10 of 14 patents shown.
Pro members see all 14.
Pro members: see all 14 patents
Also on record, not counted in the 14: 21 patents in force now held by others · 19 lapsed for an unpaid fee · 1 past the fee grace period · 1 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 5 abandoned · 8 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited